NDAORALTABLETPriority Review
Approved
Aug 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
5/8 — Partial
Priority Review
XENAZINE (tetrabenazine) by Bausch + Lomb is vesicular monoamine transporter 2 inhibitors [moa]. Approved for vesicular monoamine transporter 2 inhibitor [epc]. First approved in 2008.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XENAZINE (tetrabenazine) is an oral small-molecule vesicular monoamine transporter 2 (VMAT2) inhibitor approved in 2008 for the treatment of chorea associated with Huntington's disease. It works by depleting monoamine neurotransmitters in the central nervous system, reducing involuntary movements. This mechanism is unique among movement disorder treatments and addresses a significant unmet need in a rare disease population.
$9.0MPart D
LOE ApproachingLOE approaching signals defensive positioning and likely smaller team focused on retention and managed decline rather than growth.
Mechanism of Action
Vesicular Monoamine Transporter 2 Inhibitors
Pharmacologic Class:
Vesicular Monoamine Transporter 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
Started Jun 2026
25 enrolled
Tardive DyskinesiaIntellectual DisabilityDevelopmental Disabilities
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
Started Feb 2024
50 enrolled
Huntington's DiseaseChorea
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Started Nov 2021
30 enrolled
Huntington Disease
An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia
Started Apr 2021
15 enrolled
Dystonia, Primary
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Started Aug 2019
63 enrolled
Cerebral Palsy, Dyskinetic
Worked on XENAZINE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.